#45 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Clinicians need to understand that Ohio’s enforcement of licensed cannabis retail channels will reduce patient exposure to unregulated, potentially contaminated or mislabeled THC products that lack quality testing and potency verification. This regulatory change affects counseling conversations about cannabis safety, as patients will have greater access to standardized products with known THC content, improving the ability to provide dosing guidance and monitor for adverse effects. The policy creates clearer distinctions between medical and recreational products in the marketplace, which helps clinicians distinguish between their patients’ access to regulated medical cannabis versus illicit alternatives when assessing cannabis use patterns and related health risks.
Ohio’s Senate Bill 56, effective March 20, 2026, establishes legal authority for law enforcement to remove intoxicating THC products from unlicensed retailers, addressing the proliferation of unregulated cannabis products in the state’s market. This regulatory action distinguishes between licensed medical and adult-use cannabis dispensaries, which operate under state oversight and quality standards, and illicit retailers selling products without testing, labeling, or potency verification. The enforcement mechanism aims to reduce patient and consumer exposure to contaminated or mislabeled products that may contain harmful additives, inconsistent THC concentrations, or synthetic cannabinoids. For clinicians, this regulatory clarity is clinically relevant because patients obtaining cannabis from unlicensed sources face unpredictable pharmacological effects and safety risks that complicate medical management and informed consent discussions. Clinicians should counsel patients to obtain cannabis exclusively from state-licensed dispensaries and document the source of products their patients are using to better assess therapeutic outcomes and adverse effects. The practical takeaway is that physicians should explicitly advise patients to purchase cannabis only from regulated, licensed retailers to ensure product safety and accurate dosing information.
“What we’re seeing with SB 56 in Ohio is overdue regulatory enforcement that protects patients from contaminated and mislabeled products, but we need to be clear that removing black market access doesn’t automatically solve the problem if licensed dispensaries aren’t accessible or affordable for the communities that need them most. The clinical reality is that patients will seek cannabis whether it’s regulated or not, so enforcement without equitable access just shifts risk rather than eliminating it.”
💊 Ohio’s SB 56 represents an important regulatory step to reduce access to uncontrolled cannabis products through unlicensed retailers, which may help mitigate some harms associated with high-potency, unregulated THC formulations. However, clinicians should recognize that enforcement effectiveness will depend on resource allocation and implementation capacity at the local level, and that removing unlicensed products does not address the broader clinical challenge of rising THC concentrations even within legal markets. Patients with cannabis use disorder, those at risk for cannabis hyperemesis syndrome, or individuals with underlying psychiatric vulnerabilities may still encounter potent products through legal channels, and the policy does not establish any corresponding clinical screening or counseling infrastructure. Practically, providers should remain alert to the timeline of this regulation and use its implementation as an opportunity to proactively screen patients about cannabis use, discuss product potency concerns, and provide evidence-based harm reduction or treatment guidance
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: